SEC Form 4 · accession 0001179110-17-015218
Tabula Rasa HealthCare, Inc. · TRHC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Bruce Luehrs
Director
Period of report
Dec 8, 2017
Accepted (ET)
Dec 11, 2017 · 5:08 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001651561
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF4,F2,F3 | Dec 8, 2017 | S | 206,000 | $25.85 | D | 548,842 | I | See footnotes |
| Common StockF5,F2,F3 | Dec 11, 2017 | S | 63,000 | $25.85 | D | 485,842 | I | See footnotes |
| Common StockF1 | holding | — | — | — | 8,161 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Includes a restricted stock award of 2,596 shares of the Company's common stock received by Bruce Luehrs on June 16, 2017. Such common stock vests in full on the earlier of the next annual shareholder meeting or the one year anniversary of the date of grant.
- F2These securities are held by Emerald Stage2Ventures, L.P. Stage2 Capital Ventures Associates, L.P. is the general partner of Emerald Stage2 Ventures, L.P. and Stage2 Capital Associates G.P., LLC is the general partner of Stage2 Capital Ventures Associates, L.P. Bruce Luehrs, who serves as a director of the Issuer, is an officer of Stage2 Capital Associates G.P., LLC.
- F3The Reporting Person disclaims beneficial ownership (as defined in Rule 16a-1(a)(2)) of the securities reported herein (except to the extent of his pecuniary interest in such securities), and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.
- F4Represents shares of the Company's common stock sold by Emerald Stage2Ventures, L.P. in an underwritten public offering completed on December 8, 2017 at a price per share of $25.85, after deducting underwriting discounts and commissions of $1.65 per share.
- F5Represents shares of the Company's common stock sold by Emerald Stage2Ventures, L.P. upon the exercise of the underwriters' over-allotment option in an underwritten public offering completed on December 11, 2017 at a price per share of $25.85, after deducting underwriting discounts and commissions of $1.65 per share.